FIELD: medicine.
SUBSTANCE: present invention refers to immunology. What is contemplated is an antibody which specifically binds sphingosine-1-phosphate (S1P), and its antigen-binding fragment. There are presented a pharmaceutical composition, an antibody expression vector, a host cell, as well as a method of treating an S1P-related disease or disorder.
EFFECT: use of the invention can find further application in treating various S1P-related diseases.
17 cl, 26 ex, 11 tbl, 13 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL ANTIBODIES | 2008 |
|
RU2490277C2 |
| CHIMERIC AND HUMANISED INTEGRIN α5β1 ANTIBODIES MODULATING ANGIOGENESIS | 2003 |
|
RU2346701C2 |
| COMPOSITIONS OF ANTIBODIES | 2014 |
|
RU2694055C2 |
| METHODS OF INHIBITING OCULAR ANGIOGENESIS | 2009 |
|
RU2530583C2 |
| COMBINED THERAPY WITH USING ALPHA5BETA1 ANTAGONISTS | 2007 |
|
RU2465282C2 |
| ANTI-ANGIOGENESIS THERAPY FOR TREATING PREVIOUSLY TREATED BREAST CANCER | 2010 |
|
RU2576027C2 |
| HUMANISED ANTI-TGF-BETA-ANTIBODY | 2005 |
|
RU2386638C2 |
| VERSIONS OF IMMUNOGLOBULIN AND THEIR APPLICATION | 2009 |
|
RU2536937C2 |
| ANTI-panNrp ANTIBODY (VERSIONS) | 2007 |
|
RU2454427C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING AND VEGF ANTAGONISTS | 2013 |
|
RU2689760C2 |
